Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population : results from the population-based Rotterdam Study by Billar, Ryan J et al.
CARDIOVASCULAR DISEASE
Measures of subclinical cardiac dysfunction and increased filling
pressures associate with pulmonary arterial pressure in the general
population: results from the population-based Rotterdam Study
Ryan J. Billar1 • Maarten J. G. Leening1,2,3 • Daphne Merkus2 • Guy G. O. Brusselle1,4 • Albert Hofman1,3 •
Bruno H. Ch. Stricker1,5,6 • H. Ardeschir Ghofrani7 • Oscar H. Franco1 • Henning Gall1,7 • Janine F. Felix1
Received: 14 March 2017 / Accepted: 6 December 2017 / Published online: 13 December 2017
 The Author(s) 2017. This article is an open access publication
Abstract
Pulmonary hypertension is associated with increased mortality and morbidity in the elderly population. Heart failure is a
common cause of pulmonary hypertension. Yet, the relation between left heart parameters reflective of subclinical cardiac
dysfunction and increased filling pressures, and pulmonary arterial pressures in the elderly population remains elusive.
Within the population-based Rotterdam Study, 2592 unselected participants with a mean age of 72.6 years (61.4% women)
had complete echocardiography data available. We studied the cross-sectional associations of left heart structure and
systolic and diastolic function with echocardiographically measured pulmonary artery systolic pressure. Mean pulmonary
artery systolic pressure was 25.4 mmHg. After multivariable-adjustment measures of both structure and function were
independently associated with pulmonary artery systolic pressure: E/A ratio [0.63 mmHg (95% CI 0.35–0.91) per 1-SD
increase], left atrial diameter [0.79 mmHg (0.50–1.09) per 1-SD increase], E/E0 ratio [1.27 mmHg (0.92–1.61) per 1-SD
increase], left ventricular volume [0.62 mmHg (0.25–0.98) per 1-SD increase], fractional shortening [0.45 mmHg
(0.17–0.74) per 1-SD increase], aortic root diameter [- 0.43 mmHg (- 0.72 to - 0.14) per 1-SD increase], mitral valve
deceleration time [- 0.31 mmHg (- 0.57 to - 0.05) per 1-SD increase], and E0 [1.04 mmHg (0.66–1.42) per 1-SD
increase]. Results did not materially differ when restricting the analyses to participants free of symptoms of shortness of
breath. Structural and functional echocardiographic parameters of subclinical cardiac dysfunction and increased filling
pressures are associated with pulmonary arterial pressures in the unselected general ageing population.
Keywords Echocardiography  Pulmonary artery systolic pressure  Pulmonary hypertension  Heart failure 
Epidemiology  Population-based
Introduction
Pulmonary hypertension can occur idiopathically or, most
frequently, in association with a number of common clin-
ical conditions, including heart failure and chronic
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obstructive pulmonary disease [1, 2]. Pulmonary hyper-
tension represents the extreme form of increased pul-
monary artery systolic pressure (PASP). Both pulmonary
hypertension and increased PASP within its normal range
are associated with significant morbidity and mortality,
both in patients with underlying disorders and in the gen-
eral population [1–3]. However, increased PASP often
remains undetected until it is advanced, likely due to its
nonspecific symptoms, including shortness of breath and
fatigue [1–4].
Heart failure is a common cause of pulmonary hyper-
tension. Underlying left ventricular failure represents the
clinical phenotype on the extreme end of a continuum of
left heart function. Yet, data on the relation between left
heart parameters reflective of subclinical cardiac dysfunc-
tion and increased filling pressures, and pulmonary arterial
pressures are scarce, especially in the elderly population at
risk for heart failure [2, 5, 6]. Therefore, we aimed to
determine the associations of echocardiographically mea-
sured left heart parameters across the full spectrum with
PASP in the general ageing population.
Methods
Study population and setting
This study was conducted within the Rotterdam Study, an
ongoing prospective population-based cohort study, started
in 1990 in Rotterdam, the Netherlands. The rationale and
design of the Rotterdam Study have been described in
detail elsewhere [7, 8]. In short, the Rotterdam Study
started in 1990–1993 (RS-I, 7983 participants of 55 years
and older). Two additional subcohorts (RS-II, 3011 par-
ticipants of 55 years and older, and RS-III, 3932 partici-
pants of 45 years and older) were recruited in 2000–2001
and 2006–2008, respectively. Every 3–4 years, participants
undergo a home interview and clinical examinations at the
Rotterdam Study research center. Data on clinical diag-
noses of comorbidities, such as heart failure, are collected
continuously throughout follow-up [9].
All 4423 participants who visited the research center
during the fifth examination of RS-I (2009–2011), the third
examination of RS-II (2011–2012) and the second exami-
nation of RS-III (2012) were eligible for this analysis. We
excluded participants who did not undergo echocardiog-
raphy (mostly due to logistic reasons), those with poor
quality of echocardiography, and those in whom tricuspid
valve regurgitation values were too small to measure,
making it impossible to calculate echocardiographically
measured pulmonary artery systolic pressure (ePASP). We
also excluded participants without measurements of resting
heart rate or body surface area, which were used as key co-
variables. Our final analyses included 2592 participants
(Fig. 1).
Echocardiography
Resting transthoracic 2-dimensional echocardiography was
performed by experienced echocardiographers, using an
identical standardized protocol for all participants and
using a commercially available ultrasonography system
(Vivid I, GE Healthcare, Little Chalfont, UK), with a
2.5 MHz transducer. The protocol included 2-dimensional
scanning in the parasternal long and short axis views, the
apical and subcostal views. In addition, 2-dimension gui-
ded M-mode measurements of left ventricle and aortic root
were obtained by scanning in the parasternal long axis
view. Tissue Doppler imaging (TDI) was done in the apical
4-chamber view. All images were digitally stored and
assessed offline by the echocardiographers.
Left-sided measurements were aortic root diameter
(AoD), left atrial diameter (LAD), left ventricular end
diastolic diameter (LVEDD), left ventricular end systolic
diameter (LVESD), interventricular septum thickness
(IVST), and left ventricular posterior wall thickness
(LVPWT). Left ventricular mass (LVmass) in grams was
calculated according to the formula by Devereux and col-
leagues as 0.8 * {1.04 * ([LVEDD ? IVST ? LVPWT]3
- LVEDD3)} ? 0.6 [10]. Left ventricular volume (LVvol)
in milliliters was calculated according to the formula by
Teichholz and colleagues as 7 * LVEDD3/(2.4 ? LVEDD)
[11]. Left ventricular fractional shortening (LVFS) was cal-
culated as (LVEDD-LVESD)/LVEDD * 100% [12].
Pulsed wave Doppler in the apical 4-chamber view was
used to measure the early transmitral ventricular diastolic
filling velocity (E wave) and late diastolic filling velocity
(A wave) during 3 cardiac cycles. TDI was used to measure
the early diastolic longitudinal filling velocity of the septal
mitral annulus (E0) during 3 cardiac cycles. The means of
the E wave, A wave and E0 over the 3 cardiac cycles were
calculated and used to calculate E/A ratio and E/E0 ratio.
Mitral valve deceleration time was measured as the time
between the peak E-top wave and the upper deceleration
slope extrapolated to the zero baseline using a Continuous
Wave Doppler.
ePASP was calculated as the sum of the estimated right
atrial pressure (RAP, based on inferior vena cava diameter
and forced inspiratory collapse) and the pressure gradient
over the tricuspid valve. RAP was estimated according to
the algorithm recommended by the ASE/EAE/CSE [13]: if
the inferior vena cava diameter was B 21 mm and its
forced inspiratory collapse (‘‘sniff test’’) was[ 50%, RAP
was considered to be 3 mmHg (n = 1939); if the diameter
was[ 21 mm and the collapse\ 50%, RAP was consid-
ered as 15 mmHg (n = 41); in intermediate cases, a value
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of 8 mmHg was assigned (n = 380). Tricuspid regurgita-
tion peak velocity (TRV) was measured using Continuous
Wave Doppler. The tricuspid pressure gradient was esti-
mated using the simplified Bernoulli formula as 4 * TRV2
[13]. Thus, ePASP was estimated as 4 * TRV2 ? RAP. All
232 participants with measured TRV values but missing
RAP were assigned a conservative RAP of 3 mmHg.
Shortness of breath
Shortness of breath was assessed during the home inter-
view, which included the following question: ‘‘Do you ever
have shortness of breath?’’. If the answer was yes, the
participant was asked ‘‘Do you have shortness of breath at
rest?’’. If the answer was no, the participant was asked ‘‘Do
you have shortness of breath when walking on a flat sur-
face?’’. If the answer was no, the participant was asked
‘‘Do you have shortness of breath when climbing stairs?’’.
If participants answered no to the first question, or if they
answered yes to the first question but no to the other 3, they
were classified as being free of significant shortness of
breath. This is in line with the New York Heart Association
(NYHA) validity class I [14].
Co-variables
Information routinely collected in every follow-up round of
the Rotterdam Study includes anthropometrics, cardiovas-
cular risk factors, and medication use. Body surface area in
m2 was calculated as 0.007184 * (height in cm)0.725 * (-
weight in kg)0.425 [15]. Resting heart rate was measured
during blood pressure measurement using an Omron M7
pulse blood pressure monitoring device. Heart rate was
measured twice with a time-interval of 5 min between both
Fig. 1 Flow chart of study
participants
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measurements. The mean of the 2 measurements was used
in the analyses. Medication use was coded according to the
Anatomical Therapeutical Chemical coding system of the
World Health Organization [16].
Statistical analyses
We fitted multivariable linear regression models to study
the cross-sectional association of ePASP as the dependent
variable with each of the following independent echocar-
diographic variables separately: LAD, AoD, mitral valve
deceleration time, IVST, LVPWT, LVmass, LVvol,
LVEDD, left ventricular fractional shortening, E/A ratio,
and E/E0 ratio. All models were adjusted for sex, age,
resting heart rate, and body surface area.
We also fitted a larger multivariable-adjusted linear
regression model with ePASP as the dependent variable
and LAD, AoD, mitral valve deceleration time, LV mass,
LVvol, left ventricular fractional shortening, E/A ratio,
E/E0 ratio, and E0, as well as sex, age, resting heart rate, and
body surface area. LVvol and LVmass are calculated based
on the measured LVEDD, IVST, and LVPWT. Therefore,
we chose to use the clinically more relevant measures of
LVvol and LVmass in the larger model instead of the
underlying measurements.
We also analyzed the effect of clinical categories of E/A
ratio and E/E0 ratio instead of using the continuousmeasures.
E/A ratio was divided into three categories: B 0.75,[ 0.75
and\ 1.50, andC 1.50.We divided E/E0 ratio also into three
categories: B 8,[ 8 and\ 15, and C 15 [17, 18]. To study
whether our results were driven by symptomatic individuals
we repeated the analysis in participants free of significant
shortness of breath. We tested for potential interaction
between the echocardiographic variables and sex by adding
multiplicative interaction terms to the regression models.
The interaction terms were not significant after Bonferroni
correction for multiple testing (P value cutoff was 0.00625),
thus we did not stratify by sex.
Effect estimates are presented as bs (both per unit
increase and per 1-standard deviation (SD) increase in the
left-sided measurement) with 95% confidence intervals
(95% CIs). We considered P values of\ 0.05 statistically
significant. All analyses were done using IBM SPSS
Statistics version 21.0 (IBM Corp., Somers, NY, USA).
Results
Participant characteristics and echocardiographic mea-
surements are presented in Table 1. The mean age was 72.6
(SD 8.7) years and 61.4% of the participants were women.
The mean ePASP was 25.4 (SD 6.7) mmHg. A total of
2.8% of participants included in this analysis had an ePASP
of[ 40 mmHg or, in absence of an RAP measurement, a
TRV[ 3.0, which indicates pulmonary hypertension based
on echocardiography.
In the basic model, all parameters studied were signifi-
cantly related to ePASP, except for IVST. Table 2 and
Fig. 2a show the results per unit and per 1-SD increase,
respectively. The variables with the strongest associations
with ePASP were LAD, E/A ratio, E/E0 ratio, and LVvol.
In the larger multivariable-adjusted model, ePASP was
associated with E/A ratio [0.63 mmHg (95% CI 0.35–0.91)
per 1-SD increase], LAD [0.79 mmHg (0.50–1.09) per
1-SD increase], E/E0 ratio [1.27 mmHg (0.92–1.61) per
1-SD increase], and LVvol [0.62 mmHg (0.25–0.98) per
1-SD increase], LVFS [0.45 mmHg (0.17–0.74) per 1-SD
increase], AoD [- 0.43 mmHg (- 0.72 to - 0.14) per
1-SD increase], E0 [1.04 mmHg (0.66–1.42) per 1-SD
increase], and mitral valve deceleration time
[- 0.31 mmHg (- 0.57 to - 0.05) per 1-SD increase].
Table 2 and Fig. 3a show the results per 1-unit and per
1-SD increase in measurements, respectively. The direc-
tions of effect for all associations remained the same as in
the basic models (Table 2 and Fig. 2a), except for LVFS,
which was associated with a lower ePASP in the basic
model and with a higher ePASP in the large model.
When restricting the analysis to the 1604 participants
free of shortness of breath in the larger model, point esti-
mates were similar to those obtained in the full study
population. Table 3 and Fig. 3a show the results per 1-unit
and per 1-SD increase in the left heart measurements,
respectively. In the larger model, all echocardiographic
parameters remained significantly associated with ePASP,
except LVmass, fractional shortening and mitral valve
deceleration time. In this model the strongest associations
with ePASP were found for LAD, LVvol, E/A ratio, E/E0
ratio, and E0. Table 3 and Fig. 3b show the results per
1-unit and per 1-SD increase in the left heart measure-
ments, respectively.
Discussion
In our study among older community-dwelling adults,
structural and functional left heart parameters reflective of
subclinical cardiac dysfunction and increased filling pres-
sures were associated with ePASP. Most of the associations
persisted when we restricted the analysis to participants
free of shortness of breath, implying that these associations
are not driven by individuals with overt heart failure.
Our findings corroborate with three recent other epi-
demiologic studies. The first included 6598 male recruits
from the Israeli air force. The authors reported significant
associations of, LAD, and LVEDD with ePASP [6]. Fur-
thermore, LVmass was not significantly related to ePASP
406 R. J. Billar et al.
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Table 1 Demographic, clinical
and echocardiographic
characteristics of included
participants, n = 2592
Mean (SD) or n (%)
Age (years) 72.6 (8.7)
Women 1591 (61.4%)
Height (cm) 167 (9)
Weight (kg) 75.0 (13.4)
Body surface area (m2) 1.83 (0.19)
Body mass index (kg/m2) 26.9 (4.0)
Systolic blood pressure (mmHg) 147 (22)
Diastolic blood pressure (mmHg) 84 (11)
Resting heart rate (bpm) 68 (11)
History of chronic obstructive pulmonary
disease
267 (10.3%)
History of atrial fibrillation 163 (6.9%)
Shortness of breatha
Validity class I 1711 (73.2%)
Validity class II 220 (9.4%)
Validity class III 271 (11.6%)
Validity class VI 135 (5.8%)
Smoking
Never 944 (36.4%)
Former 1377 (53.2%)
Current 269 (10.4%)
History of diabetes mellitus 243 (9.6%)
Blood pressure-lowering drugs 1131 (55.9%)
Diuretics 465 (23.0%)
b-blockers 639 (31.6%)
Calcium channel blockers 232 (11.5%)
RAAS inhibitors 640 (31.7%)
Other 15 (0.7%)
Cholesterol-lowering drugs 617 (30.5%)
Echocardiography
Pulmonary arterial systolic pressure (mmHg) 25.4 (6.7)
Pulmonary arterial systolic
pressure[ 40 mmHg
73 (2.8%)
Left ventricular mass (gram) 130 (38)
Left ventricular volume (mL) 126 (31)
Interventricular septum thickness (mm) 8 (2)
Left ventricular posterior wall thickness (mm) 7 (1)
Diameter of left atrium (mm) 42 (6)
Left ventricular fractional shortening (%) 42 (6)
Left ventricular end-diastolic dimension (mm) 51 (5)
Diameter of the aortic root (mm) 34 (4)
E/A ratio 0.93 (0.35)
B 0.75 741 (29.9%)
[ 0.75 and\ 1.50 1636 (66.1%)
C 1.50 98 (4.0%)
E/E0 ratio 11.0 (4.8)
B 8 620 (23.1%)
[ 8 and\ 15 1714 (63.8%)
C 15 352 (13.1%)
E0 (m/s) 0.07 (0.02)
Mitral valve inflow deceleration-time (ms) 204 (42)
Missing values for data on traditional cardiovascular risk factors ranged from 0 to 2.8%
Missing values for data on left heart echocardiographic parameters ranged from 0.2 to 1.7%, with exception
of E/A ratio with 5.2% (mainly due to atrial fibrillation)
bpm beats per minute, E/A ratio E wave divided by A wave, E/E0 ratio E wave divided by E0, HDL high
density lipid protein, RAAS renin–angiotensin–aldosterone system
aValidity classes according to the New York Heart Association (NYHA) [14], data available in 90.2% of
the participants
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in the Israeli study, which is in line with our findings. In
contrast to our findings, the authors observed no significant
association of LVFS with ePASP. This difference might be
explained by the differences in age and health status of the
study participants. When we restricted our analysis to
participants without shortness of breath, and hence to the
healthier part of our population, left ventricular fractional
shortening was also no longer significantly related to
ePASP in our study. The second study was done in 1480
younger Italians (mean age 36 years) free of structural
heart disease. Results were similar, with a significant
association of left ventricular stroke volume and E/E0 ratio
with ePASP and no significant association with left ven-
tricular mass index [4]. The third study included 3282
middle-aged African-Americans (mean age 56 years) and
evaluated echocardiographic correlates of pulmonary
hypertension rather than the entire spectrum of pulmonary
artery pressures [5]. This study reported a significant
association for LAD and for LV ejection fraction\ 50%
with presence of pulmonary hypertension. These results are
overall in line with ours, although the latter association
with LV systolic function attenuated in our multivariable-
adjusted analysis.
Mechanisms
We hypothesized that left-sided echocardiographic
parameters across the full spectrum would be associated
with ePASP, as early alterations in left heart structure and
function can herald increased filling pressures and manifest
heart failure, which is a common cause of pulmonary
hypertension. Remarkably, LVFS showed a change in the
direction of effect after multivariable-adjustment. This
warrants further research to elucidate the underlying
mechanisms involved.
Also, we observed that a greater AoD was associated
with a lower ePASP. A similar association between AoD
and ePASP was reported in the Israeli study [6]. The
Framingham Heart Study previously reported an associa-
tion between higher arterial systolic blood pressure and
aortic root size in a population-based setting [19]. Con-
comitant stiffening of both the aortic and pulmonary artery
Table 2 Associations of individual left heart echocardiographic parameters with ePASP
Full study population, n = 2592 Restricted to free of shortness of breath,
n = 1711
Difference (95% CI) in ePASP P value Difference (95% CI) in ePASP P value
Left ventricular mass (per 10 grams) 0.23 (0.15 to 0.30) \ 0.001 0.19 (0.10 to 0.29) \ 0.001
Left ventricular volume (per 10 mL) 0.26 (0.27 to 0.35) \ 0.001 0.22 (0.11 to 0.34) \ 0.001
Left ventricular posterior wall thickness (mm) 0.28 (0.05 to 0.51) 0.016 0.28 (0.00 to 0.55) 0.048
Interventricular septum thickness (per 1 mm) 0.15 (- 0.02 to 0.32) 0.078 0.12 (- 0.09 to 0.32) 0.264
Diameter of left atrium (per 1 mm) 0.27 (0.22 to 0.31) \ 0.001 0.25 (0.19 to 0.30) \ 0.001
Left ventricular fractional shortening (per 1%) - 0.07 (- 0.12 to - 0.03) 0.002 - 0.05 (- 0.11 to 0.01) 0.102
Left ventricular end-diastolic dimension (per 1 mm) 0.14 (0.09 to 0.20) \ 0.001 0.13 (0.06 to 0.19) \ 0.001
Diameter of the aortic root (per 1 mm) - 0.12 (- 0.20 to - 0.05) 0.001 - 0.15 (- 0.24 to - 0.07) 0.001
Mitral valve inflow deceleration-time (per 10 ms) - 0.22 (- 0.28 to - 0.15) \ 0.001 - 0.20 (- 0.27 to - 0.13) \ 0.001
E/A ratio 3.94 (3.23 to 4.65) \ 0.001 3.60 (2.67 to 4.53) \ 0.001
B 0.75 0.00 (reference) 0.00 (reference)
[ 0.75 and\ 1.50 1.55 (0.98 to 2.12) \ 0.001 1.47 (0.79 to 2.15) \ 0.001
C 1.50 6.24 (4.94 to 7.54) \ 0.001 5.69 (4.05 to 7.32) \ 0.001
E/E0 ratio 0.27 (0.22 to 0.32) \ 0.001 0.27 (0.19 to 0.35) \ 0.001
B 8 0.00 (reference) 0.00 (reference)
[ 8 and\ 15 1.08 (0.46 to 1.70) 0.001 1.09 (0.36 to 1.83) 0.003
C 15 3.36 (2.44 to 4.28) \ 0.001 3.36 (2.24 to 4.48) \ 0.001
E0 (per 0.1 m/s) 2.51 (1.12 to 3.89) \ 0.001 2.77 (1.11 to 4.42) 0.001
Adjusted for age, sex, resting heart rate, and body surface area
ePASP echocardiographic pulmonary artery systolic pressure, SD standard deviation, CI confidence interval, E/A ratio E wave divided by A
wave, E/E0 ratio E wave divided by E0
cFig. 2 Associations of individual left heart echocardiographic param-
eters with ePASP. a Total study population, n = 2592, b restricted to
study population without symptoms of shortness of breath, n = 1711.
Adjusted for age, sex, resting heart rate, and body surface area
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Fig. 3 Multivariable-adjusted associations of left heart echocardio-
graphic parameters with ePASP. a Total study population, n = 2400,
b restricted to study population without symptoms of shortness of
breath, n = 1604. Adjusted for age, sex, heart rate, body surface area,
and all other left heart echocardiographic parameters in this figure
410 R. J. Billar et al.
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walls, reducing the compliance of both, might explain these
findings. This reduced compliance would cause a higher
pulse pressure in the aortic root and a higher pressure in the
pulmonary artery, as well as a smaller aortic root diameter
[19]. However, this hypothesis warrants further funda-
mental experimental research.
Limitations
Some limitations of our study need to be addressed. First,
right heart catheterization is the gold standard for pul-
monary arterial pressure measurements, but due to its
invasiveness, heart catheterization is not suitable for pop-
ulation-based studies. However, several studies have
shown that ePASP correlates well with invasively mea-
sured pulmonary arterial pressure and that echocardiogra-
phy is appropriate for measurement of PASP in this setting
[20, 21]. Also, the largest differences between pulmonary
pressure measured by heart catheterization and echocar-
diography arise in those with high pressures [22]. The vast
majority of the included participants had pressure estimates
in the normal range. Second, TRV measurements could not
be assessed in 621 participants (Fig. 1 and Table 1), pre-
dominantly because of technical difficulties in adequately
visualizing the tricuspid valve. These participants were on
average older (mean age 74.7 years), had a higher BMI
(mean BMI 32.0 kg/m2), had a slightly worse left ven-
tricular systolic function (mean LVFS 40%), and were
more likely to report shortness of breath (47.5%). Thus,
these participants were overall less healthy. Another 850
participants had undergone echocardiography, but had no
tricuspid regurgitation or too small to quantify indicating
they had a very low ePASP. These missing values will have
affected the distribution of the studied echocardiographic
parameters in our sample and resulted in an overestimation
of the average ePASP, but are unlikely to have affected the
b-estimates since we found no indications for nonlinearity
in the data. Third, our population was older (mean age
72.6 years) and predominantly white (96.5%). Our results
should therefore be extrapolated with caution to younger
populations or those of other ethnic origins. Last, we did
not have data available on more advanced or novel
echocardiographic parameters, such as volumetric tracings,
tissue Doppler-derived systolic function, and measures of
strain.
Clinical perspectives
Our work should be considered preclinical as this is the
first study in the community-dwelling ageing population to
demonstrate that parameters of subclinical left heart dys-
function and increased filling pressures correlate with
Table 3 Multivariable-adjusted associations of left heart echocardiographic parameters and ePASP
Full study population, n = 2400 Restricted to free of shortness of breath,
n = 1604
Difference (95% CI) in ePASP P value Difference (95% CI) in ePASP P value
Left ventricular mass (per 10 grams) 0.08 (- 0.02 to 0.17) 0.117 0.06 (- 0.06 to 0.18) 0.202
Diameter of left atrium (per 1 mm) 0.13 (0.08 to 0.18) \ 0.001 0.14 (0.09 to 0.20) \ 0.001
Left ventricular fractional shortening (per 1%) 0.08 (0.03 to 0.13) 0.002 0.06 (- 0.00 to 0.12) 0.067
Left ventricular volume (per 10 mL) 0.19 (0.08 to 0.31) 0.001 0.21 (0.07 to 0.36) 0.004
Diameter of the aortic root (per 1 mm) - 0.11 (- 0.18 to - 0.04) 0.003 - 0.14 (- 0.23 to - 0.06) 0.001
Mitral valve inflow deceleration-time (per 10 ms) - 0.07 (- 0.14 to - 0.01) 0.021 - 0.06 (- 0.13 to 0.02) 0.124
E/A ratio 1.88 (1.05 to 2.71) \ 0.001 1.39 (0.29 to 2.49) 0.013
B 0.75 0.00 (reference) NA 0.00 (reference) NA
[ 0.75 and\ 1.50 0.40 (- 0.21 to 1.01) 0.197 0.36 (- 0.37 to 1.10) 0.329
C 1.50 2.90 (1.50 to 4.31) \ 0.001 2.48 (0.71 to 4.25) 0.006
E/E0 ratio 0.28 (0.20 to 0.36) \ 0.001 0.36 (0.24 to 0.48) \ 0.001
B 8 0.00 (reference) NA 0.00 (reference) NA
[ 8 and\ 15 1.05 (0.38 to 1.72) 0.002 1.52 (0.71 to 2.34) \ 0.001
C 15 2.84 (1.69 to 3.98) \ 0.001 3.82 (2.41 to 5.24) \ 0.001
E0 (per 0.1 m/sec) 5.23 (3.32 to 7.14) \ 0.001 6.47 (4.00 to 8.94) \ 0.001
Adjusted for age, sex, resting heart rate, body surface area, and all other continuous left heart echocardiographic parameters in this table
ePASP echocardiographic pulmonary artery systolic pressure, SD standard deviation, CI confidence interval, E/A ratio E wave divided by A
wave, E/E0 ratio E wave divided by E0
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subtle increases in pulmonary pressures. It remains to be
studied whether progression to overt symptomatic pul-
monary hypertension could be halted or controlled by
pharmacological treatment in persons with subclinical left
heart disease [23–26].
Conclusion
Structural and functional echocardiographic parameters of
subclinical cardiac dysfunction and increased filling pres-
sures are associated with pulmonary arterial pressures in
the unselected general ageing population.
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